Cyclerion Therapeutics (CYCN) Share-based Compensation (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Share-based Compensation of $300000.0 for Q3 2025, up 117.39% year-over-year from $138000.0 in Q3 2024, and up 163.16% quarter-over-quarter from $114000.0 in Q2 2025.
Cyclerion Therapeutics (CYCN) Share-based Compensation (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $300000.0 for Q3 2025.
- In Q3 2025, Share-based Compensation rose 117.39% year-over-year to $300000.0; the TTM figure through Sep 2025 stood at $300000.0 (down 50.5% YoY), while the FY2024 annual figure was $625000.0, down 41.42% from the prior year.
- Share-based Compensation for Q3 2025 stood at $300000.0, up from $114000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $2.5 million in Q4 2021, with the low at $103000.0 in Q4 2023.
- The 5-year median for Share-based Compensation is $379000.0 (2023), against an average of $951736.8.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation plunged 90.84% in 2023, then surged 117.39% in 2025.
- Cyclerion Therapeutics' Share-based Compensation stood at $2.5 million in 2021, then tumbled by 55.87% to $1.1 million in 2022, then slumped by 90.84% to $103000.0 in 2023, then increased by 18.45% to $122000.0 in 2024, then surged by 145.9% to $300000.0 in 2025.
- Business Quant data shows CYCN's Share-based Compensation at $300000.0 in Q3 2025, $114000.0 in Q2 2025, and $114000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | - |
| 10 | Cyclerion Therapeutics | 12.38 Mn | 9.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Mar 31, 2025 | 114,000.00 |
| Mar 31, 2025 | 114,000.00 |
| Dec 31, 2024 | 122,000.00 |
| Dec 31, 2024 | 122,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 184,000.00 |
| Mar 31, 2024 | 181,000.00 |
| Mar 31, 2024 | 181,000.00 |
| Dec 31, 2023 | 103,000.00 |
| Dec 31, 2023 | 103,000.00 |
| Sep 30, 2023 | 159,000.00 |
| Sep 30, 2023 | 159,000.00 |
| Jun 30, 2023 | 379,000.00 |
| Jun 30, 2023 | 379,000.00 |